1. Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example
- Author
-
David Christopher Ebner, Paula M. Loria, David Hepworth, Edward L. Conn, Janice E. Chin, Lucy Rogers, Kevin J. Filipski, Philip A. Carpino, Shawn Cabral, Maria A. Vanvolkenburg, Lisa D. Norquay, John R. Hadcock, Aaron C. Smith, Kimberly O. Cameron, Markus Boehm, Esther C.Y. Lee, Denise Gautreau, Martin B. Brenner, Michelle Morin, Peter C. Bonnette, and Alan M. Mathiowetz
- Subjects
Chemistry ,Transgene ,Organic Chemistry ,Druggability ,Computational biology ,Bioinformatics ,Biochemistry ,Small molecule ,law.invention ,law ,Drug Discovery ,Recombinant DNA ,Signal transduction ,Receptor ,Integral membrane protein ,G protein-coupled receptor - Abstract
Orphan G protein-coupled receptors (oGPCRs) are a class of integral membrane proteins for which endogenous ligands or transmitters have not yet been discovered. Transgenic animal technologies have uncovered potential roles for many of these oGPCRs, providing new targets for the treatment of various diseases. Understanding signaling pathways of oGPCRs and validating these receptors as potential drug targets requires the identification of chemical probe compounds to be used in place of endogenous ligands to interrogate these receptors. A novel chemical probe identification platform was created in which GPCR-focused libraries were screened against sets of oGPCR targets, with a goal of discovering fit-for-purpose chemical probes for the more druggable members of the set. Application of the platform to a set of oGPCRs resulted in the discovery of the first reported small molecule agonists for GPR39, a receptor implicated in the regulation of insulin secretion and preservation of beta cells in the pancreas. Compound 1 stimulated intracellular calcium mobilization in recombinant and native cells in a GPR39-specific manner but did not potentiate glucose-stimulated insulin secretion in human islet preparations.
- Published
- 2013